NCT07855627

Brief Summary

To find out whether the BIA test can help identify participants with IBC who are at risk for developing lymphedema.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P50-P75 for all trials

Timeline
39mo left

Started Sep 2026

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress1%
Sep 2026Dec 2029

Study Start

First participant enrolled

September 16, 2026

Completed
13 days until next milestone

First Submitted

Initial submission to the registry

September 29, 2026

Completed
3 days until next milestone

First Posted

Study publicly available on registry

October 2, 2026

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2027

Expected
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2029

Last Updated

October 2, 2026

Status Verified

September 1, 2026

Enrollment Period

1.3 years

First QC Date

September 29, 2026

Last Update Submit

September 29, 2026

Conditions

LymphedemaInflammatory Breast Cancer (IBC)PreoperativeBioimpedance Measurement

Outcome Measures

Primary Outcomes (1)

  • Lymphedema Life Impact Scale (LLIS) questionnaire

    Through study completion; an average of 1 year.

Interventions

Neoadjuvant therapyDRUG

all patients will start/continue neoadjuvant systemic therapy

Eligibility Criteria

Age18 Years+
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsFemales
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

UT MD Anderson Cancer Center

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UT MD Anderson Cancer Center

Houston, Texas, 77030, United States

RECRUITING

Related Links

MeSH Terms

Conditions

LymphedemaInflammatory Breast Neoplasms

Interventions

Neoadjuvant Therapy

Condition Hierarchy (Ancestors)

Lymphatic DiseasesHemic and Lymphatic DiseasesBreast NeoplasmsNeoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Combined Modality TherapyTherapeutics

Study Officials

  • Anthony Lucci, MD

    UT MD Anderson Cancer Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Anthony Lucci, MD

CONTACT

713-563-1871ALucci@mdanderson.org

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 29, 2026

First Posted

October 2, 2026

Study Start

September 16, 2026

Primary Completion (Estimated)

December 31, 2027

Study Completion (Estimated)

December 31, 2029

Last Updated

October 2, 2026

Record last verified: 2026-09

Locations

US(1)